KB001 ( DrugBank: KB001 )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01695343 (ClinicalTrials.gov)	December 2012	25/9/2012	Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment	A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa	Cystic Fibrosis	Biological: KB001-A;Drug: Placebo Comparator	KaloBios Pharmaceuticals	NULL	Completed	12 Years	50 Years	Both	182	Phase 2	United States;Australia;Israel;New Zealand
2	NCT00638365 (ClinicalTrials.gov)	March 2008	12/3/2008	Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa	A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa	Cystic Fibrosis	Biological: KB001;Other: Placebo	KaloBios Pharmaceuticals	NULL	Completed	12 Years	N/A	All	27	Phase 1/Phase 2	United States